



The Era of Personalized Medicine in the Landscape of Rare Tumors

Guest Editors:

Dr. Toni Ibrahim

Dr. Laura Mercatali

Dr. Alessandro De Vita

Dr. Chiara Liverani

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

The interest in personalized medicine, also referred to as precision medicine, has been rapidly growing in the last decade. This is especially evident in the field of rare tumors, which represent a heterogeneous group of solid malignancies accounting for 20–25% of all neoplasms. Today, about 250 different entities are recognized by the WHO. Their extraordinary diversity in terms of diagnosis, prognosis, and therapy affects patient management, which is still challenging compared to that of common tumor types. In order to solve the unmet scientific and clinical needs, personalized medicine has been proposed as a new window of opportunity.

This Special Issue will cover all aspects around recent advancements in the field of personalized medicine in the panorama of rare tumors. Original articles, reviews, and case reports are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)